Every material Form 8-K Arrowhead Pharmaceuticals filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Arrowhead reported fiscal 2025 results for the year ended September 30, 2025, with revenue of $829.4 million, up from $3.6 million a year earlier. The company's net loss attributable to Arrowhead narrowed to $1.6 million, or $0.01 per diluted share, from $599.5 million, or $5.00 per share, in fiscal 2024, driven largely by milestone payments from Sarepta Therapeutics and the Novartis licensing deal.
Revenue was $829.4 million for fiscal 2025 versus $3.6 million for fiscal 2024.
Operating income was $98.3 million versus an operating loss of $601.1 million a year earlier.
Net loss attributable to Arrowhead was $1.6 million, or $0.01 per diluted share, versus $599.5 million, or $5.00 per share.
The FDA approved REDEMPLO (plozasiran) for adults with familial chylomicronemia syndrome, and the company received a $200 million upfront payment from Novartis.
Arrowhead Pharmaceuticals entered an exclusive license and collaboration agreement with Novartis for ARO-SNCA, a preclinical RNA interference therapy for Parkinson's Disease and other synucleinopathies, plus additional collaboration targets. Arrowhead will receive a $200 million upfront payment upon closing and is eligible for up to $2 billion in milestones and tiered royalties up to the low double digits on net sales, but the deal remains subject to closing conditions including the Hart-Scott-Rodino waiting period.
Upfront payment of $200 million to Arrowhead, payable upon closing
Eligible for up to $2 billion in development, regulatory and sales milestones, plus royalties up to the low double digits
Novartis takes sole control of clinical development, manufacturing and commercialization after Arrowhead completes preclinical work
Transaction expected to close in the second half of 2025, subject to Hart-Scott-Rodino and other customary conditions
Arrowhead Pharmaceuticals reported results for the fiscal 2025 third quarter ended June 30, 2025, with revenue of $27.8 million compared with none a year earlier. The net loss attributable to the company was $175.2 million, up from $170.8 million, while the diluted loss per share narrowed to $1.26 from $1.38. The filing also described a $130 million upfront payment from Sanofi tied to a Greater China deal for a majority-owned subsidiary, and a $100 million Sarepta milestone payment.
Revenue of $27.8 million in the quarter, versus $0 in the same period a year earlier
Net loss attributable to Arrowhead of $175.2 million, versus $170.8 million a year earlier; diluted loss per share of $1.26, versus $1.38
Research and development expenses of $162.4 million and general and administrative expenses of $30.9 million
Total cash resources of $900.4 million as of June 30, 2025, and a PDUFA action date of November 18, 2025 for plozasiran
Arrowhead Pharmaceuticals reported fiscal second-quarter 2025 results for the period ended March 31, 2025, with revenue of $542.7 million versus none a year earlier and net income attributable to the company of $370.4 million, compared with a loss of $125.3 million in the prior-year quarter. The company also said it expects to be funded into 2028 following its Sarepta Therapeutics agreement, and that its CFO, Ken Myszkowski, will retire effective May 13, 2025, succeeded by Daniel Apel.
Revenue was $542.7 million for the quarter, compared with $0 in the year-earlier period.
Net income attributable to Arrowhead was $370.4 million, or $2.75 per diluted share, versus a loss of $1.02 per share a year earlier.
Research and development expenses rose to $133.1 million from $101.1 million.
CFO Ken Myszkowski retires effective May 13, 2025; Daniel Apel succeeds him.
Arrowhead Pharmaceuticals said CFO Ken Myszkowski will retire effective May 13, 2025, after serving as CFO since 2009, and will stay on as an employee adviser through January 31, 2026. Daniel Apel, formerly Global Head of Financial Planning and Analysis at Walgreens Boots Alliance, will succeed him as CFO. The company describes the retirement as not the result of any disagreement.
Ken Myszkowski retires as CFO effective May 13, 2025; he has served as CFO since 2009
Daniel Apel appointed CFO; target bonus set at 45% of base salary
Apel to receive a one-time grant of 100,000 restricted stock units vesting annually over four years, plus up to $200,000 in relocation benefits
Myszkowski's transition adviser role runs until January 31, 2026, at a $200,000 annual base salary
Arrowhead Pharmaceuticals reported results for the fiscal 2025 first quarter ended December 31, 2024. Revenue was $2.5 million versus $3.551 million a year earlier, and the net loss attributable to the company widened to $173.1 million, or $1.39 per diluted share, from $132.9 million, or $1.24 per share. The company said it is funded into 2028 and cited the Sarepta licensing agreement and the plozasiran NDA acceptance as recent progress.
Revenue of $2.5 million for the quarter, compared with $3.551 million a year earlier
Net loss attributable to Arrowhead of $173.1 million, or $1.39 per diluted share, versus $132.9 million, or $1.24 per share, a year earlier
Total cash resources of $552.9 million at December 31, 2024, down from $681.0 million at September 30, 2024
Sarepta agreement provides $825 million upon closing, including $500 million in cash and a $325 million equity investment
Arrowhead appointed Douglas Ingram, President and CEO of Sarepta Therapeutics, as a director effective February 6, 2025, under an Investor Rights Agreement with Sarepta. The filing ties the appointment to the Collaboration Agreement and Stock Purchase Agreement with Sarepta, which the filing says closed on February 7, 2025, and makes Mr. Ingram not independent under Nasdaq rules.
Douglas Ingram appointed director effective February 6, 2025; appointment made under Investor Rights Agreement with Sarepta dated November 25, 2024
Sign-on grant of restricted stock units valued at $771,200, scheduled to vest over three years
Mr. Ingram is President and CEO of Sarepta; the Collaboration and Stock Purchase Agreements with Sarepta closed February 7, 2025
Filing states Mr. Ingram is not considered an independent director under Nasdaq Listing Rules
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Arrowhead Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →